After software entrepreneur Marty Thomas survived Stage 4 non-Hodgkin lymphoma, he and wife MariKate started raising chickens ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

CD19-targeted CAR T cells have transformed the management of patients with relapsed and/or refractory large B cell lymphoma, and these therapies are increasingly being administered as earlier-line ...

A six-year-old playful girl’s limp was dismissed by doctors as “growing pains” until an MRI scan revealed non-Hodgkin's lymphoma, a type of blood cancer. Meredith thereafter underwent extensive ...

Unlike Hodgkin lymphoma, the non-Hodgkin varieties look different under the microscope and don’t contain Reed-Sternberg cells. T-cell lymphoma is a type of non-Hodgkin lymphoma. Non-Hodgkin ...

A recent study has provided new insights into the long-term safety of commercially available CD19-targeted chimeric antigen receptor (CAR)-T cell therapy for adult patients with aggressive B cell ...